15
2022-05
Kintor Pharma Included in MSCI China Index
Suzhou, May 15, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company’s stock has been included in the MSCI China Index, effective May 31, 2022.
04
2022-05
Suzhou, May 4, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in the United States of its multi-regional phase II clinical trial (NCT05178043) of ALK-1 antibody (GT90001) and Nivolumab (Opdivo) combination therapy for the treatment of advanced Hepatocellular Carcinoma (HCC) on 2 May 2022.
06
2022-04
Suzhou, April 6, 2022, 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results of the Phase III MRCT of proxalutamide in outpatients with mild to moderate COVID-19 regardless of vaccination status and risk factors.
03
2022-04
Kintor Pharma Announces Two Upcoming Poster Presentations at AACR 2022
Suzhou, April 3, 2022 - 真人直营投注网站 (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year’s AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
25
2022-03
Kintor Pharma Announces 2021 Business Progress and Annual Results
Suzhou, March 25, 2022 - 真人直营投注网站 (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended December 31, 2021.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn